Objective To investigate the value of 99Tcm-hydrazinonicotinamide(HYNIC)-prostate specific membrane antigen(PSMA)SPECT/CT imaging in biochemical recurrence of prostate cancer(PCa).Methods From January 2018 to March 2023,112 patients with biochemical recurrence of PCa(age(72.6±6.1)years)who underwent 99Tcm-HYNIC-PSMA SPECT/CT imaging in Henan Provincial People's Hospital were retrospectively analyzed.According to the level of prostate specific antigen(PSA),patients were divided into 0.2 pg/L<PSA≤1 pg/L group,1 pg/L<PSA≤2 μg/L group,and PSA>2 μg/L group.According to the Gleason score,patients were divided into Gleason score≥8 group and Gleason score<8 group.The detection rate between groups was analyzed by x2 test,and the difference of the PSA level be-tween groups was compared by Mann-Whitney U test.Results PSMA imaging was positive in 77 cases and negative in 35 cases,with the detection rate of 68.8%(77/112).The detection rates of local recurrence,lymph node metastasis,bone metastasis and lung metastasis were 8.9%(10/112),43.8%(49/112),28.6%(32/112)and 0.9%(1/112),respectively.The detection rates of 0.2 μg/L<PSA≤1 μg/L,1 µg/L<PSA≤2 μg/L and PSA>2 μg/L groups were 44.7%(21/47),8/12 and 90.6%(48/53),respectively(x2=24.44,P<0.001).The detection rates of Gleason score ≥8 group and<8 group were 76.4%(55/72)and 55.0%(22/40)(x2=5.47,P=0.032);the PSA level between the two groups was statistically different(3.11(0.75,5.91)and 0.84(0.44,2.92)μg/L;z=-2.99,P=0.003).Of the patients with PSMA posi-tive imaging,84.4%(65/77)changed their treatment regimen and 15.6%(12/77)continued to observe or maintain the original treatment plan.Of the patients with PSMA negative imaging,40.0%(14/35)changed the treatment plan,51.4%(18/35)continued to observe or maintain the original treatment plan,and 8.6%(3/35)discontinued the original treatment because no tumor metastasis was found.Conclusion 99 Tcm-HYNIC-PSMA SPECT/CT imaging can provide reference for the lesion detection,treatment decision-making and follow-up observation of biochemical recurrence of PCa.